Adding abemaciclib, a CDK-4/6 inhibitor, to a nonsteroidal aromatase inhibitor improved overall survival in postmenopausal women with HR+/HER2− advanced breast cancer, although the results did not reach statistical significance. The MONARCH 3 study involved 493 patients who had not received prior systemic therapy in the advanced setting. Patients receiving abemaciclib had a median overall survival of 66.8 months compared to 53.7 months in the placebo arm. The PFS benefit of abemaciclib was maintained at 8 years follow-up. While the overall survival results were not statistically significant, the authors emphasized the clinical relevance of the findings. The study was funded by Eli Lilly, with various authors disclosing relationships with industry.
Source link
A Benefit to Add-On Abemaciclib in Advanced Breast Cancer?
